|
|
||||||||
J Thorac Cardiovasc Surg 1999;118:1157
© 1999 Mosby, Inc.
LETTERS TO THE EDITOR |
Department of Cardiovascular Surgery, Centre Hospitalier Universitaire Xavier Bichat
Paris, Francea
Institut de Pharmacologie Moleculaire et Cellulaire, CNRS UPR 411, Sophia Antipolis
06560 Valbonne, Franceb
Reply to the Editor:
We thank Miyamoto and Miyamoto for their interest in our recent article.
1 It is a fact that ketamine is a widely known N -methyl-D -aspartate receptor antagonist that has demonstrated neuroprotective properties in vitro and in vivo.
2 Therefore the observed neuroprotective effect in our study is the result of ketamine and riluzole effects. Ketamine has been widely used by most investigators working with the rabbit model of spinal cord ischemia, with minor spinal cord protection afforded by this drug.
2,3 In our study, all rabbits received the same dose of ketamine, with huge differences in neurologic recovery among experimental groups. Thus, although the potentiating effect of ketamine cannot be ruled out, it is unlikely that this drug by itself could account for the dramatic differences in neurologic recovery among experimental groups. For definitive assessment of the neuroprotective effects of riluzole, we have performed a new study with a spinal cord ischemia model in the rat.
4 All animals were anesthetized with halothane 1.5% only, and they received riluzole before aortic crossclamping and at the onset of reperfusion. Rats were allowed to recover for 24 (n = 15), 48 (n = 10), or 96 hours (n = 5). In this study, riluzole again prevented neuronal necrosis and apoptosis and cytoskeletal proteolysis.
Regarding neurologic recovery of rabbits, we did not observe worsening of neurologic status in riluzole-treated rabbits between 24 and 120 hours after the operation. Rabbits were scored at 6 hours, 24 hours, and then daily. Riluzole-treated rabbits typically began to recover motor and sensory function between 6 and 24 hours after the operation, whereas control rabbits did not. Neurologic scoring before 6 hours would have been inappropriate considering the anesthetic properties of riluzole. In our recent study, control rats remained severely paraplegic after the operation, whereas riluzole-treated rats began to recover at 6 hours and had either completely normal neurologic function or a mild to moderate deficit up to 96 hours postoperatively.
This result is of importance because some neuroprotective drugs can modify the early recovery but finally fail to alter the mid-term and late recovery after spinal cord ischemia.
5 Riluzole, however, not only has a transient effect, but also may really and consistently prevent spinal cord ischemic injury when given before aortic crossclamping.
References
This article has been cited by other articles:
![]() |
A.R. Casha, M. Gauci, L. Yang, M. Saleh, P.H. Kay, and G.J. Cooper Fatigue testing median sternotomy closures Eur. J. Cardiothorac. Surg., March 1, 2001; 19(3): 249 - 253. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |